Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

@article{Perez2015GenomicAR,
  title={Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.},
  author={Edith A. Perez and E. Aubrey Thompson and Karla V. Ballman and Stephanie Anderson and Yan W. Asmann and Krishna R. Kalari and Jeanette E. Eckel-Passow and Amylou C Dueck and Kathleen S. Tenner and Jin Jen and Jian-Bing Fan and Xochiquetzal J. Geiger and Ann E. McCullough and Beiyun Chen and R. Brian Jenkins and George W. Sledge and Eric P. Winer and Julie R. Gralow and Monica M. Reinholz},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2015},
  volume={33 7},
  pages={701-8}
}
PURPOSE To develop a genomic signature that predicts benefit from trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. PATIENTS AND METHODS DASL technology was used to quantify mRNA in samples from 1,282 patients enrolled onto the Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer (North Central Cancer Treatment Group N9831 [NCCTG-N9831]) adjuvant trastuzumab trial. Cox proportional hazard ratios (HRs), adjusted for significant… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 99 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 67 extracted citations

Similar Papers

Loading similar papers…